Relapsed Refractory Multiple Myeloma (RRMM) Latest Advances

Find the Latest Research About Relapsed Refractory Multiple Myeloma (RRMM)

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 214 publications

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma
Published: December 02, 2025

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Journal: Blood cancer journal
Published: October 13, 2025

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Journal: Future oncology (London, England)
Published: September 15, 2025

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Journal: Blood cancer journal
Published: September 08, 2025

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Journal: Blood reviews
Published: July 25, 2025

Chimeric antigen receptor T-cell therapy for multiple myeloma.

Chimeric antigen receptor T-cell therapy for multiple myeloma.

Journal: Current opinion in oncology
Published: July 17, 2025

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Journal: Clinical lymphoma, myeloma & leukemia
Published: July 06, 2025

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Journal: Blood cancer journal
Published: July 01, 2025

Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.

Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.

Journal: Transplantation and cellular therapy
Published: May 31, 2025

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.

Journal: Haematologica
Published: May 21, 2025

Trends in compassionate use of medicinal products: Israel 2020-2024.

Trends in compassionate use of medicinal products: Israel 2020-2024.

Journal: Israel journal of health policy research
Published: May 07, 2025

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Journal: Blood cancer journal
Published: May 04, 2025
Showing 1-12 of 214

Last Updated: 02/24/2026